哪里想瘦打哪里！FDA批准Kythera注射用药上市在即

你才双下巴，你全家都双下巴！所谓爱美之心人皆有之。如果说赘肉是每一个努力保有完美外貌的“妹纸”或“汉纸”的大敌，那么一个喜感十足的双下巴可谓是这些人的生死作对了。每一分钟，世界各地都有人为自己的一张大饼脸而倍感烦恼，虽然保有一个肉感十足的双下巴槌上来是挺有肉感的，但是还是有很多人的心理素质使其无法承受一个双下巴之重。您可千万别笑，这甚至已经催生出一个相当可观的零售商。根据英国脸部外科手术协会的调查报告研究说明了，68%的英国人对自己的双下巴表示了“无聊”之情。而迫切需要，值得注意Kythera的公司向FDA提交了其专门剿灭双下巴的护肤麻醉固定式本品ATX-101。这种本品已完成了许多“胖纸”梦寐以求的功能，哪里想瘦打哪里，可谓是定点节食。切勿以为这种即便如此任性的本品只是一个笑话，在FDA的下属的脸部和眼科本品专员会的无记名投票者里面，专家可是以17：0的超高票数一致赞同其纳斯达克。或许是因为这些专家里面也有很多屡遭双下巴之苦吧。FDA也将计划于月份的5月13日以后对其作出终于决定。如果一切顺利的话，Kythera的公司计划于月份下半年将该产品纳斯达克，分析部分人预计这一本品的年销售额将超过3亿美元之多。随着护肤本品零售商的日益加大，Kythera的公司可谓是下了一步好棋。的公司于月内以8400万美元的定价从其前的公司拜耳手里面收回了这种本品的全部权利。而Kythera的公司也努力以此为契机在护肤本品零售商里面攻城拔寨。就在上个月，Kythera的公司和Actelion的公司陷入僵局价值2700万美元的协作协议，共同整合一种失败过的抗病毒炎症本品，而这种本品被认为有可能整合出一种治疗高血压的本品。详细法文报道：Kythera ($KYTH) won the unanimous support of an FDA advisory panel for its fat-busting injection, rolling toward approval with a first-of-its-kind treatment.The agency's independent Dermatologic and Ophthalmic Drugs Advisory Committee voted 17-0 that the drug's benefits outweighed its risks for patients looking to reduce submental fat, or double chin. The FDA is not required to follow its panels' votes, though it most commonly does, and the agency has promised to make a final decision on the injection by May 13. If all goes according to plan, Kythera plans to launch the drug, ATX-101, in the second half of this year.The biotech's shares he more than tripled since it pulled off a $73 million IPO in 2012, rising steadily as investors bet ATX-101 can carve out a space on the aesthetic market and potentially lure a Big Pharma acquirer. Kythera is pitching the injection as a much-needed nonsurgical option for double chin reduction, citing an American Society for Dermatologic Surgery survey that estimates 68% of Americans are "bothered" by submental fat.Kythera regained full rights to ATX-101's potential last year, orchestrating an $84 million deal to buy out ex-partner Bayer. And the drug, a synthetic version of the fat-blasting deoxycholic acid, could bring in more than $300 million a year once approved, Leerink yst Seamus Fernandez has said."This milestone demonstrates our commitment to developing first-in-class aesthetic products through a focus on scientific rigor and innovation," Kythera CEO Keith Leonard said in a statement. "At Kythera, we remain focused on investing in novel treatments that will allow aesthetic physicians to better meet the needs of their patients."Kythera is also focused on raising some cash now that it has a likely approval ahead. The biotech filed for a $125 million offering as soon as the market closed on Monday. Its share price was down several points at the end of the day.Beyond its top prospect, Kythera is working to build out a pipeline of aesthetic medicines. Last month, the California biotech signed a $27 million deal with Actelion ($ATLN) to get its hands on a once-failed anti-inflammatory medicine that could he a future as a treatment for hair loss.